1 / 18

Strategic Pharma Issues

Strategic Pharma Issues . Dr. Brian W Tempest www.briantempest.com brian.tempest@clara.co.uk Mumbai, India January 2013. A Slide from a UK Headhunter. Asian Growth source: Bangkok Post 26 July 2012. The Biggest Healthcare Fraud in History

elisabeth
Download Presentation

Strategic Pharma Issues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Strategic Pharma Issues Dr. Brian W Tempest www.briantempest.com brian.tempest@clara.co.uk Mumbai, India January 2013

  2. A Slide from a UK Headhunter

  3. Asian Growthsource: Bangkok Post 26 July 2012

  4. The Biggest Healthcare Fraud in History Source: Daily Mail 3 July 2012

  5. A Pfizer Decade of Briberysource: FT August 7 2012

  6. Big Pharma Business Model Brokensource: Pharmatimes World News April 2012

  7. USA Life Expectancy & Pharma CostsSource: US Health in International Perspective Jan 2013

  8. The Strategic Changes by Big PharmaSource: FT December 5 2012, Franz Humer, Roche Chairman • Possible to cut 30-50% off development costs via CT efficiencies • Shift from product focus to patient focus using diagnostic tools • In Europe there isn’t one Government or politician interested in the health of the Industry • USA & Latin American countries open to rewarding innovation • Industry has to change fundamentally how it manages costs • Leaner headquarters & smaller central functions • Division of the industry into 2 parts • A Innovative businesses able to charge a premium price • B Large scale manufacturers who can compete on cost

  9. Patent Expiries to 2018source: EvaluatePharma 2012

  10. The Teva Future – Standing StillSource: RBC Capital 12 December 2012

  11. Teva Losing Control of Costs in the EUsource: Teva June 2012

  12. Reference Pricing in Central Europe Source : Istanbul September 2012 • Pharma purchases reduced from 1.7% of GDP to 1.0% of GDP in Turkey • Russia, South Korea & Saudi Arabia health ministries now requesting Turkish prices • Everybody is referencing everybody else on Pharma prices in Europe • Bulgaria is currently referencing prices in 17 other countries

  13. BiosimiIar Issues in EU/USA • Rituximab –100 pat Roche, >600 pat Generics • Interchangeability unlikely • Could be different INN name in USA and EU • Cabilly patents may delay US mAbs to 2018 • EU first mAb in 2013 from Hospira/Celltrion • Pharmacovigilance data needed • EPO side effects in Thailand widely quoted • 400 biosimilar manufacturers in China but none will reach EU/USA • Biobetters need a full dossier with health economic data

  14. Sandoz Biosimilars – an 18 years ROIsource: Pharmacloud June 2012

  15. NIBS (tyrosine kinase inhibitors)Will these small molecules replace mAbs? • Axitinib, Pfizer, cancer • Cediranib, AZ, cancer • Pazopanib, GSK, cancer • Regorafenib, Bayer, cancer • Semaxanib, Sugen, cancer • Sorafenib, Bayer(Nexavar),cancer • Sunitinib, Pfizer, cancer • Toceranib, Pfizer, cancer • Vandetanib, AZ, cancer • Tofactinib, Pfizer, RA

  16. Hisun-Pfizer JV to have 1500 staff in 2013source: Fierce Pharma

  17. Walgreens, Boots, Nanjing AxisSource: FT Sep 16 2012

  18. Thank You brian.tempest@clara.co.uk www.briantempest.com

More Related